<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00007644</url>
  </required_header>
  <id_info>
    <org_study_id>407</org_study_id>
    <nct_id>NCT00007644</nct_id>
    <nct_alias>NCT00002606</nct_alias>
  </id_info>
  <brief_title>Prostate Cancer Intervention Versus Observation Trial (PIVOT)</brief_title>
  <acronym>PIVOT</acronym>
  <official_title>CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical prostatectomy provides potentially curative removal of the cancer. However, it
      subjects patients to the morbidity and mortality of the surgery and may be neither necessary
      nor effective. Expectant management does not offer potential cure. However, it provides
      palliative therapy for symptomatic or metastatic disease progression, avoids potentially
      excessive and morbid interventions in asymptomatic patients, and emphasizes management
      approaches for focus on relieving symptoms while minimizing therapeutic complications.

      The primary objective of this study is to determine which of two strategies is superior for
      the management of clinically localized CAP: 1) radical prostatectomy with early aggressive
      intervention for disease persistence or recurrence, 2) expectant management with reservation
      of therapy for palliative treatment of symptomatic or metastatic disease progression.
      Outcomes include total mortality, CAP mortality, disease free and progression free survival,
      morbidity, quality of life, and cost effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Hypothesis: To determine whether radical prostatectomy or expectant management is
      more effective in reducing mortality and extending life.

      Secondary Hypothesis: To determine which treatment strategy is superior in terms of prostate
      specific cancer mortality, quality of life, occurrence or recurrence of symptoms and need for
      cancer treatment.

      Intervention: 1) Radical prostatectomy, plus intervention for evidence of disease persistence
      or recurrence, 2) Expectant management with palliative therapy reserved for symptomatic or
      metastatic disease progression.

      Primary Outcomes: All cause mortality.

      Study Abstract: Cancer of the prostate (CAP) is the most common nondermatologic and the
      second most frequent cause of cancer deaths in men. No cure is currently possible for
      disseminated disease. Cancer confined to the prostate is believed to be curable, with the
      most frequently recommended therapy being surgical extirpation of the tumor with radical
      prostatectomy. However, despite increasing cancer detection and aggressive surgical
      treatment, population-based mortality rates from prostate cancer have not decreased, neither
      nationally nor in states with high rates of radical prostatectomy. Existing evidence does not
      demonstrate the superiority of this procedure compared to expectant management in the
      treatment of localized prostate cancer. Data from case series suggest that either treatment
      approach provides equivalent all-cause as well as prostate cancer specific mortality. The
      only randomized trial was limited by a small sample size but the results favored expectant
      management.

      Radical prostatectomy provides potentially curative removal of the cancer. However, it
      subjects patients to the morbidity and mortality of the surgery and may be neither necessary
      nor effective. Expectant management does not offer potential cure. However, it provides
      palliative therapy for symptomatic or metastatic disease progression, avoids potentially
      excessive and morbid interventions in asymptomatic patients, and emphasizes management
      approaches for focus on relieving symptoms while minimizing therapeutic complications.

      The primary objective of this study is to determine which of two strategies is superior for
      the management of clinically localized CAP: 1) radical prostatectomy with early aggressive
      intervention for disease persistence or recurrence, 2) expectant management with reservation
      of therapy for palliative treatment of symptomatic or metastatic disease progression.
      Outcomes include total mortality, CAP mortality, disease free and progression free survival,
      morbidity, quality of life, and cost effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1994</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>Annual</time_frame>
    <description>Annually, from date of randomization until the date of death from any cause, assessed up to 8 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>bi-annual</time_frame>
    <description>Bi-annually, from date of randomization until the date of death from any cause, assessed up to 8 years.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">731</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radical Prostatectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical removal of the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Watchful Waiting</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Closely watching, waiting and treating symptoms if and when cancer progresses</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical prostatectomy</intervention_name>
    <description>Surgical removal of the prostate</description>
    <arm_group_label>Radical Prostatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinically localized CAP

          -  Diagnosis of Prostate Cancer within previous 6 months

          -  Age 75 years or younger

        Exclusion Criteria:

        PSA &gt; 50 ng/ml Bone scan consistent with metastatic disease Other evidence that cancer of
        the prostate is not clinically localized Diagnosis of prostate cancer greater than 12
        months ago Life expectancy less than 10 years Serum creatinine greater than 3 mg/dl
        Myocardial infarction within last 6 months Unstable angina New York Heart Association Class
        III or IV congestive heart failure Severe pulmonary disease Lifer failure Severe dementia
        Debilitating illness Malignancies, except for nonmelanomatous skin cancer, in the last 5
        years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J. Wilt, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Minneapolis VA Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock</name>
      <address>
        <city>No. Little Rock</city>
        <state>Arkansas</state>
        <zip>72114-1706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles HCS, Sepulveda</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <zip>91343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veterans Hospital, Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VAMC (WestSide Division)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Roudebush VA Medical Center, Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-2884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Iowa City</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246-2208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overton Brooks VA Medical Center, Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA New Jersey Health Care System, East Orange</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Stratton Medical Center, Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Harbor Health Care System, Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Western New York Healthcare System at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Health Care System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Providence</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System, Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Veterans Health Care System</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Hampton</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23667</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Clarksburg</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wlliam S. Middleton Memorial Veterans Hospital, Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wilt T. Expectant management or early intervention for clinically localized prostate cancer? What we need are randomized trials. Clinical Care For Prostatic Diseases. 1994 Jan 6; 1:1-9.</citation>
  </results_reference>
  <results_reference>
    <citation>Moon TD, Brawer MK, Wilt TJ. Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. J Natl Cancer Inst Monogr. 1995;(19):69-71.</citation>
    <PMID>7577210</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ, Brawer MK. Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. Semin Urol. 1995 May;13(2):130-6.</citation>
    <PMID>7638470</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt T, Brawer M. The Prostate Cancer Intervention versus Observation Trial. Cancer. 1995 May 12; 75:1963-1968.</citation>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Williston Park). 1997 Aug;11(8):1133-9; discussion 1139-40, 1143. Review.</citation>
    <PMID>9268976</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt T. The importance of randomized treatment trials in early stage prostate cancer. New Developments in Prostate Cancer and Treatment. 1997 Feb 21; 2:29-35.</citation>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ. Prostate cancer screening: practice what the evidence preaches. Am J Med. 1998 Jun;104(6):602-4.</citation>
    <PMID>9674725</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ. Uncertainty in prostate cancer care: the physician's role in clearing the confusion. JAMA. 2000 Jun 28;283(24):3258-60.</citation>
    <PMID>10866876</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ. Prostate carcinoma practice patterns: what do they tell us about the diagnosis, treatment, and outcomes of patients with prostate carcinoma? Cancer. 2000 Mar 15;88(6):1277-81.</citation>
    <PMID>10717606</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt T. Editorial comment. Urology. 2001 Nov 1; 58(6):964-965.</citation>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer. Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.</citation>
    <PMID>11828353</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ. SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care. J Natl Cancer Inst. 2008 Aug 20;100(16):1123-5. doi: 10.1093/jnci/djn259. Epub 2008 Aug 11.</citation>
    <PMID>18695131</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM Jr; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006 Jan;175(1):217-20; discussion 220-1.</citation>
    <PMID>16406915</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162. Erratum in: N Engl J Med. 2012 Aug 9;367(6):582.</citation>
    <PMID>22808955</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ. Implications of the prostate intervention versus observation trial (PIVOT). Asian J Androl. 2012 Nov;14(6):815. doi: 10.1038/aja.2012.103. Epub 2012 Sep 17.</citation>
    <PMID>22983306</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec;2012(45):184-90. doi: 10.1093/jncimonographs/lgs041.</citation>
    <PMID>23271771</PMID>
  </results_reference>
  <results_reference>
    <citation>Barry MJ, Andriole GL, Culkin DJ, Fox SH, Jones KM, Carlyle MH, Wilt TJ. Ascertaining cause of death among men in the prostate cancer intervention versus observation trial. Clin Trials. 2013;10(6):907-14. doi: 10.1177/1740774513498008. Epub 2013 Aug 29.</citation>
    <PMID>23988464</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilt TJ, Scardino PT, Carlsson SV, Basch E. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. Epub 2014 Mar 4.</citation>
    <PMID>24594482</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2000</study_first_submitted>
  <study_first_submitted_qc>December 30, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2001</study_first_posted>
  <results_first_submitted>August 15, 2013</results_first_submitted>
  <results_first_submitted_qc>November 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2014</results_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer of the prostate (CAP)</keyword>
  <keyword>cancer treatment</keyword>
  <keyword>chronic diseases</keyword>
  <keyword>expectant management</keyword>
  <keyword>genitourinary</keyword>
  <keyword>prostate</keyword>
  <keyword>prostate specific cancer mortality</keyword>
  <keyword>radical prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment begain in November 1994 and ended in January 2002 with follow-up through January 2010. We recruited men from 44 Department of Veterans Affairs sites and 8 National Cancer Institute sites.</recruitment_details>
      <pre_assignment_details>A total of 13,022 men were entered into study logs as potentially eligible. Based upon further chart review, 6707 met age, comorbidity and prostate cancer specific criteria and received detailed information about the study. From these, 5023 were considered likely to be eligible and a total of 731 men agreed to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Radical Prostatectomy</title>
          <description>Surgical removal of the prostate</description>
        </group>
        <group group_id="P2">
          <title>Watchful Waiting</title>
          <description>Closely watching, waiting and treating symptoms if and when cancer progresses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="367"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="367"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radical Prostatectomy</title>
          <description>Surgical removal of the prostate</description>
        </group>
        <group group_id="B2">
          <title>Watchful Waiting</title>
          <description>Closely watching, waiting and treating symptoms if and when cancer progresses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="364"/>
            <count group_id="B2" value="367"/>
            <count group_id="B3" value="731"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="5.2"/>
                    <measurement group_id="B2" value="66.8" spread="5.6"/>
                    <measurement group_id="B3" value="66.9" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Cause Mortality</title>
        <description>Annually, from date of randomization until the date of death from any cause, assessed up to 8 years.</description>
        <time_frame>Annual</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All Cause Mortality</title>
        <description>Bi-annually, from date of randomization until the date of death from any cause, assessed up to 8 years.</description>
        <time_frame>bi-annual</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radical Prostatectomy</title>
            <description>Surgical removal of the prostate</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting</title>
            <description>Closely watching, waiting and treating symptoms if and when cancer progresses</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <description>Bi-annually, from date of randomization until the date of death from any cause, assessed up to 8 years.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" lower_limit="41.9" upper_limit="52.1"/>
                    <measurement group_id="O2" value="49.9" lower_limit="44.8" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Radical Prostatectomy</title>
          <description>Surgical removal of the prostate</description>
        </group>
        <group group_id="E2">
          <title>Watchful Waiting</title>
          <description>Closely watching, waiting and treating symptoms if and when cancer progresses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="367"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="171" subjects_affected="171" subjects_at_risk="364"/>
                <counts group_id="E2" events="183" subjects_affected="183" subjects_at_risk="367"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="367"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy Wilt, MD</name_or_title>
      <organization>Minneapolis VA Medical Center</organization>
      <phone>612-467-2158</phone>
      <email>timothy.wilt@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

